Sundrug raises non-consolidated profit forecasts on new dividend income

Sundrug Co., Ltd. announced a significant upward revision to its non-consolidated financial results forecasts for the fiscal year ending March 31, 2026. For the six months ending September 30, 2025, the ordinary profit forecast increased by 49.2% to JPY 18,200m, and profit for the six months rose by 71.4% to JPY 14,400m. Basic earnings per share are now projected at JPY 123.11, up from JPY 71.83.

The full fiscal year forecast also saw substantial revisions. Ordinary profit is now expected to be JPY 35,000m, a 34.6% increase, and profit for the current fiscal year is projected at JPY 27,000m, a 50.0% increase. This brings the basic earnings per share forecast to JPY 230.84, up from JPY 153.92.

The company attributes these revisions to dividend receipts from consolidated subsidiaries, as announced on August 7, 2025. These dividends, starting in December 2025, are expected to significantly increase non-consolidated profit for its drugstore business, exceeding initial estimates. This revision of non-consolidated financial forecasts will not impact consolidated financial forecasts or results.